Four new indications for durvalumab have been approved by AIFA. Mantovani (Humanitas): “We must continue to invest in research and innovation”

Immunotherapy: how clinical practice is changing for lung and bladder cancers

The clinical trials range from oncology to haematology, from cardiovascular diseases to immunology and neuroscience

Bristol Myers Squibb: “In Italia for 80 years, with 42 molecules under investigation and 120 clinical trials”

AIFA has given the go-ahead for acalabrutinib in combination with venetoclax. The drug has also been given the green light, in combination with chemo-immunotherapy, for the rarer mantle cell lymphoma

Chronic lymphocytic leukaemia: a new targeted ‘combination’ for first-line treatment

Senator Elena Murelli, first signatory of the amendment to the last budget law extending the use of this precision oncology tool, speaks

Metastatic breast cancer: 'Time to make liquid biopsy available'

The Network connects 160 clinical centres and 60 laboratories on a digital platform to promote equal access to advanced, certified molecular diagnostics and could provide access to innovative research projects

Labnet, in 20 years 200,000 examinations and 6.8 million benefit for the SSN

Conference at the ministry, flash mob and exhibition in Piazza del Popolo in Rome: the associations present an agenda with six goals to be achieved

Ovarian cancer: by 2030 reference centres for 90% of patients

Aifa approves reimbursability of darolutamide with androgen deprivation therapy: improves disease control and quality of life for patients

Prostate cancer: with innovative drugs, treatment becomes personalised

The appeal of clinicians and associations: only half of the patients manage to access the test for ESR1 mutations

Metastatic breast cancer: release 15 million for liquid biopsy

Aifa green light for a drug indicated alone in advanced stages for oesophagus and lung and together with chemo for gastric and oesophageal malignancies

Tumours, immunotherapy advances: cures for oesophagus and stomach, plus lung

Subcutaneous administration of nivolumab within minutes offers important advantages for patients with different malignancies with the same clinical efficacy

Frontiers of care